GNPX Genprex, Inc.
2.620USD+0.38%Mkt Cap: 2.15M $P/E: —1d ago
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new the…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.27BUSDP/E 30.7
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 Genprex Shares Rise After Collaboration With Roche Diagnostics Genprex Inc. (NASDAQ:GNPX) shares gained 3% on Monday after the clinical-stage biotechnology company announced a collaboration with Roche Diagnostics to validate biomarkers designed to improve patient selection in clinical trials for non-small cell lung cancer (NSCLC). | ||